Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rashkin, M. C.
Right arrow Articles by Penovich, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rashkin, M. C.
Right arrow Articles by Penovich, P.
NEUROLOGY 1987;37:500
© 1987 American Academy of Neurology

Pentobarbital treatment of refractory status epilepticus

Mitchell C. Rashkin, MD, Charles Youngs, PharmD and Patricia Penovich, MD

Departments of Internal Medicine (Pulmonary Division), Pharmacy, and Neurology, University of Cincinnati Medical Center, Cincinnati, OH.

We studied nine patients with status epilepticus refractory to standard therapy. In all patients so treated, IV pentobarbital terminated seizure activity. Mortality was high (77%) in those treated, but was attributed to underlying pathology and possibly to duration of status epilepticus. Pentobarbital therapy should be initiated within 0 to 2 hours after onset of seizures, with continuous EEG monitoring in an intensive care unit.

Address correspondence and reprint requests to Dr. Rashkin, University of Cincinnati Medical Center, Division of Pulmonary Disease, 231 Bethesda Avenue, Cincinnati, Ohio 45267–0564.

Received January 10, 1986. Accepted for publication in final form June 24, 1986.




This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
S. S. Chung, N. C. Wang, and D. M. Treiman
Comparative Efficacy and Safety of Antiepileptic Drugs for the Treatment of Status Epilepticus
Journal of Pharmacy Practice, April 1, 2007; 20(2): 137 - 146.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
S. M. Mirsattari, M. D. Sharpe, and G. B. Young
Treatment of Refractory Status Epilepticus With Inhalational Anesthetic Agents Isoflurane and Desflurane
Arch Neurol, August 1, 2004; 61(8): 1254 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M Holtkamp, F Masuhr, L Harms, K M Einhaupl, H Meierkord, and K Buchheim
The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists
J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1095 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Claassen, L. J. Hirsch, R. G. Emerson, J. E. Bates, T. B. Thompson, and S. A. Mayer
Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus
Neurology, September 25, 2001; 57(6): 1036 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
D. L. Gilbert and T. A. Glauser
Complications and Costs of Treatment of Refractory Generalized Convulsive Status Epilepticus in Children
J Child Neurol, September 1, 1999; 14(9): 597 - 601.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
D. L. Gilbert, P. S. Gartside, and T. A. Glauser
Efficacy and Mortality in Treatment of Refractory Generalized Convulsive Status Epilepticus in Children: A Meta-Analysis
J Child Neurol, September 1, 1999; 14(9): 602 - 609.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by AAN Enterprises, Inc.